Day: May 16, 2023

Strategic collaboration supports BEEAH in creating Jawaher Boston Medical District in Sharjah, United Arab Emirates

Boston, MA, May 16, 2023 (GLOBE NEWSWIRE) — Mass General Brigham and Dana-Farber Cancer Institute are collaborating with BEEAH Group, an organization pioneering sustainability and quality of life solutions in the Middle East, to advise in the development of the Jawaher Boston Medical District, a state-of-the-art health care system designed to deliver world-class, patient-centered care through innovation, technology, and sustainability. Mass General Brigham and Dana-Farber Cancer Institute are strategic partners, serving in an advisory capacity, on the project in Sharjah, United Arab Emirates, which includes a multi-specialty flagship hospital for integrated, cutting-edge care.

The collaboration combines the depth and breadth of clinical expertise and innovation from Mass General Brigham and Dana-Farber Cancer Institute, with BEEAH’s vision to create a sustainable, advanced, patient-centered health system designed to deliver care to patients within – and beyond – hospital walls. BEEAH Group was founded in 2007 to tackle sustainability challenges in Sharjah and improve quality of life.

Focused on serving the unique needs of the people of Sharjah and the region, the Jawaher Boston Medical District will offer patients access to the latest clinical expertise across a wide variety of integrated clinical specialties, including lifestyle medicine and prevention, oncology, women’s health, pediatrics, cardiovascular, neurosciences, behavioral health, and rehabilitation medicine. In addition to medical and research expertise, Mass General Brigham and Dana-Farber Cancer Institute will also collaborate with BEEAH Group to advise on best practices in workforce training, development, and public education to the community, with attention to developing local talent.

Mass General Brigham and Dana-Farber Cancer Institute are advising BEEAH Group in their development of multiple facilities, comprising the flagship hospital and ambulatory clinics across Sharjah, with integrated, innovative, and digital solutions, including app-based care and hospital-at-home.

“Mass General Brigham has a deep history of global collaboration aimed at serving and improving the lives of patients around the world,” said Raymond W. Liu, MD, Vice President, Mass General Brigham Global Advisory.  “In collaborating with BEEAH, we hope to contribute our decades of expertise to their development of a unique, innovative vision for a health system that builds on medicine’s leading edge, with an eye to the future.”

“Dana-Farber, a world leader in cancer treatment and research, is committed to advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases locally and globally,” said Adam Reich, Vice President of Business Initiatives at Dana-Farber Cancer Institute. “We are pleased to work with BEEAH and extend our expertise to this collaboration as part of our mission to enhance access to expert cancer care and reduce the burden of cancer worldwide.”

By leveraging its expertise in quality-of-life solutions in Sharjah and the Middle East, BEEAH will create a new destination for the health, wellness and quality of life for the people of Sharjah and the region focused on patient outcomes and experience gleaned from a robust academic ecosystem pioneered, developed and refined over two centuries by Mass General Brigham and Dana-Farber Cancer Institute clinicians.

By pooling their combined medical, research and sustainability expertise, Mass General Brigham, Dana-Farber Cancer Institute and BEEAH will develop innovative technologies, diagnostics, delivery models and patient care, ultimately fostering research, directly benefitting patients globally and providing valuable cross-institutional learnings in the United States. The outcome will enable BEEAH to create a comprehensive patient-centered health care system for the people of Sharjah and the UAE, integrating healthcare solutions into homes, schools, workplaces, and communities to help all patients and their families live healthier lives.

“By partnering with Mass General Brigham and Dana-Farber Cancer Institute, BEEAH Group is entering the healthcare industry and adding a new dimension to our purpose of pioneering a sustainable quality of life for the people of Sharjah, the UAE, and beyond,” said Khaled Al Huraimel, Group CEO of BEEAH Group. “Drawing from the expertise of our partners in Boston, we look forward to creating not just an integrated health network, but a future-ready healthcare ecosystem. The Jawaher Boston Medical District will provide patients in Sharjah access to world-class healthcare closer to home, while also serving as a hub for the development of cutting-edge treatments and medical advancement.”

The project draws from Mass General Brigham and Dana-Farber Cancer Institute’s medical and research expertise, as well as BEEAH Group’s experience collaborating and innovating with international partners to create facilities that are sustainable, digitally-enabled and centered around the comfort and convenience of occupants.

Following a meeting of representatives from Mass General Brigham, Dana-Farber Cancer Institute and BEEAH Group, Sheikha Jawaher Al Qasimi, Wife of the Ruler of Sharjah and Chairperson of BEEAH Group, and Meghan Gregonis, United States General Consul in Dubai, the Jawaher Boston Medical District in Sharjah was approved to move forward.

About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit www.massgeneralbrigham.org.

About Dana-Farber Cancer Institute 
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber is the only hospital with a top 4 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.

For more information, please visit www.dana-farber.org.

About BEEAH Group
BEEAH Group is the region’s leading sustainability and digitalisation expert, renowned for ground-breaking environmental innovations and smart solutions for future-ready cities. Recognising sustainability and technology as the pillars of a modern economy, BEEAH Group has invested in a comprehensive, full-circle strategy for the future. BEEAH Group operates in the industries of waste management, renewable energy, technology, consulting, education, transport, real estate and healthcare. Raising the bar for the quality of life in the region, BEEAH Group businesses continue to set industry benchmarks in sustainable, smart solutions and help countries across the region create and execute their roadmap for a socially responsible future. The Group currently operates in the UAE, Egypt and KSA. For more information, please visit www.beeahgroup.com and connect on LinkedIn, Instagram, Facebook and Twitter @beeahgroup

Noah Brown
Mass General Brigham
617-643-3907
Nbrown9@mgb.org

GlobeNewswire Distribution ID 8840712

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of The Walt Disney Company (NYSE: DIS) between December 10, 2020 and November 8, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2023.

SO WHAT: If you purchased Disney securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Disney class action, go to https://rosenlegal.com/submit-form/?case_id=16164 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The Complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Disney+ was suffering decelerating subscriber growth, losses, and cost overruns; (2) the true costs incurred in connection with Disney+ had been concealed by Disney executives by debuting certain content intended for Disney+ initially on Disney’s legacy distribution channels and then making the shows available on Disney thereafter to improperly shift costs out of the Disney+ segment; (3) Disney Media and Entertainment Distribution (“DMED”) had made platform distribution decisions based not on consumer preference, consumer behavior, or the desire to maximize the size of the audience for the content as represented, but based on the desire to hide the full costs of building Disney+ ‘s content library; (4) Disney was not on track to achieve even the reduced 2024 Disney paid global subscriber and profitability targets, such targets were not achievable, and such estimates lacked a reasonable basis; and (5) defendants had materially misrepresented the actual performance of Disney+, the sustainability of Disney+’s historical growth trends, the profitability of Disney+, and the likelihood that Disney could achieve its 2024 Disney+ subscriber and profitability targets. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Disney class action, go to https://rosenlegal.com/submit-form/?case_id=16164 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8840685

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Spirit AeroSystems Holdings, Inc. (NYSE: SPR) between April 8, 2020 and April 13, 2023, both dates inclusive (the “Class Period”), of the important July 3, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Spirit AeroSystems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Spirit AeroSystems class action, go to https://rosenlegal.com/submit-form/?case_id=15844 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Spirit lacked effective production quality controls; (2) that, as a result, Spirit incorrectly installed fittings designed to join the aft fuselage to the vertical tail for some Boeing 737 Max airplanes that Spirit sent to Boeing; (3) that, as a result, Spirit would have to develop an inspection and repair procedure for the affected fuselages; (4) that the foregoing would negatively impact Spirit’s financial results; and (5) that as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Spirit AeroSystems class action, go to https://rosenlegal.com/submit-form/?case_id=15844 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8840669

BUFFALO, NY / ACCESSWIRE / May 16, 2023 / ZeptoMetrix® is excited to introduce PROtrol ^TM, a new line of products designed for antigen-based diagnostic methods. These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.

PROtrol is the only whole organism reference material to provide complete testing data. Each lot of product is supplied with the protein concentration and TCID₅₀ value, which minimizes qualification testing. PROtrol provides better reproducibility, which optimizes the use of financial spending and processing time through the decreased need for repeat testing.

“The rapid expansion in development of antigen-based assays has highlighted some quality challenges. Inactivated, whole organism controls designed specifically for antigen tests can equip manufacturers with the tools they need to better evaluate the performance of their assays, leading to higher quality tests on the market,” said Dr. Karuna Sharma, Vice President & Chief Scientific Officer.

PROtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Isolate: USA-WA1/2020* is the first member of this product line (PROSARS(COV2)-587). As we move beyond the COVID-19 pandemic, ZeptoMetrix will continue to grow the PROtrol product line, providing high-quality controls to assay manufacturers seeking to expand access to inexpensive and easy-to-use diagnostics.

“The launch and expansion of PROtrol enhances our position as the partner of choice for diagnostic test developers,” said Evangeline Gonzalez, President of Antylia Diagnostics division. “As we work with our diagnostic partners, ZeptoMetrix is pleased with the role that PROtrol plays to give patients around the world more access to diagnostic testing.”

More information on how to order the new PROtrol and additional ZeptoMetrix products can be found at: https://www.zeptometrix.com

About ZeptoMetrix^®
ZeptoMetrix® is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

Links:
* (PROSARS(COV2)-587): product page
https://www.zeptometrix.com/products/protrolt-sars-cov-2-isolate-usa-wa1-2020-1-ml

Contact Information

Andrew Zenger
Global Product Manager
andrew.zenger@antylia.com
(716) 715-7417

Related Files

PROSARS(COV2)-587 Product Insert.pdf
ZeptoMetrix Launches PROtrol.pdf

SOURCE: ZeptoMetrix